Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amneal Pharmaceuticals, Inc. - Class A Common Stock (NQ:AMRX)

19.95 -0.26 (-1.29%)
Delayed Quote Updated: 4:00 PM EST, Nov 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Amneal Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
AMRX Q3 deep dive: biosimilars and specialty launches expand growth engines, guidance raised
Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) reported Q3 2026 results beating Wall Street’s revenue expectations, with sales up 10% year on ye... 
Via StockStory
News headline image
Amneal (AMRX) Q3 2026 Earnings Call Transcript ↗
Specialty gains offset a steep AvKARE decline in the latest quarter. 
Via The Motley Fool
Topics Earnings
News headline image
What Amneal Pharmaceuticals (AMRX) Said on Its Q3 Earnings Call ↗
Amneal Pharmaceuticals (NASDAQ:AMRX) reported third-quarter 2026 revenue of $863 million, up 10% from a year earlier, as growth in affordable medicines and specialty products more than offset an... 
Via MarketBeat
Topics Earnings
Amneal Pharmaceuticals (NASDAQ:AMRX) Beats Q3 Estimates but Cash-Flow Guidance Weighs on Shares ↗
Via Chartmill
Amneal Pharmaceuticals (NASDAQ:AMRX) Soars on Q2 Earnings Beat and Raised Guidance ↗
Via Chartmill
Topics Earnings
News headline image
Amneal (NASDAQ:AMRX) beats expectations in strong Q3 2026, full-year outlook slightly exceeds expectations
Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) reported revenue ahead of Wall Street’s expectations in Q3 2026, with revenue up 10% year on year... 
Via StockStory
News headline image
Amneal (AMRX) Q3 earnings: what to expect
Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) will be reporting results tomorrow before market hours. Here’s what to expect. Amneal beat analys... 
Via StockStory
News headline image
1 Russell 2000 Stock with Competitive Advantages and 2 Facing Challenges
The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However,... 
Via StockStory
News headline image
1 Profitable Stock for Long-Term Investors and 2 Facing Headwinds
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does... 
Via StockStory
News headline image
3 Overrated Stocks We Think Twice About
Great things are happening to the stocks in this article. They’re all outperforming the market over the last month because of positive catalysts such as a ne... 
Via StockStory
News headline image
3 Low-Volatility Stocks with Open Questions
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets. Lu... 
Via StockStory
News headline image
Why Is Amneal (AMRX) Stock Rocketing Higher Today
What Happened? Shares of pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) jumped 12.5% in the afternoon session after the company announced that t... 
Via StockStory
News headline image
3 Reasons to Avoid AMRX and 1 Stock to Buy Instead
What a time it’s been for Amneal. In the past six months alone, the company’s stock price has increased by a massive 47.7%, reaching $18.31 per share. This w... 
Via StockStory
News headline image
Generic Pharmaceuticals Stocks Q2 Results: Benchmarking Amneal (NASDAQ:AMRX)
Wrapping up Q2 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Amneal (NASDAQ:AMRX) and its peers. The g... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
1 Stock Under $50 with Solid Fundamentals and 2 Facing Challenges
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However... 
Via StockStory
News headline image
1 Russell 2000 Stock with Exciting Potential and 2 We Ignore
The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However,... 
Via StockStory
News headline image
1 Healthcare Stock Worth Your Attention and 2 We Ignore
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry... 
Via StockStory
News headline image
5 Insightful Analyst Questions From Amneal’s Q2 Earnings Call
Amneal’s second quarter results reflected ongoing momentum driven by expanded product launches and strength across its core Affordable Medicines and Specialt... 
Via StockStory
Topics Earnings World Trade
News headline image
AMRX Q2 Deep Dive: Diversified Product Mix and Biosimilars Strategy Shape Guidance
Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 9.9% year on ... 
Via StockStory
News headline image
Amneal (AMRX) Q2 2026 Earnings Call Transcript ↗
Revenue hit $796 million as biosimilar strategy accelerates with Kashiv acquisition. 
Via The Motley Fool
Topics Earnings
News headline image
Amneal Pharmaceuticals Q2 Earnings Call Highlights ↗
Amneal Pharmaceuticals (NASDAQ:AMRX) reported second-quarter 2026 revenue of $796 million, up 10% from a year earlier, as growth in its affordable medicines and specialty businesses offset a decline at... 
Via MarketBeat
Topics Earnings
News headline image
Amneal (NASDAQ:AMRX) Beats Expectations in Strong Q2 CY2026, Stock Jumps 15.9%
Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 9.9% year on ... 
Via StockStory
News headline image
Amneal (AMRX) Reports Q2: Everything You Need To Know Ahead Of Earnings
Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) will be announcing earnings results this Thursday before market hours. Here’s what to expect. Amn... 
Via StockStory
News headline image
Spotting Winners: Amneal (NASDAQ:AMRX) And Generic Pharmaceuticals Stocks In Q1
Wrapping up Q1 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Amneal (NASDAQ:AMRX) and its peers. The g... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
3 Reasons AMRX is Risky and 1 Stock to Buy Instead
Amneal currently trades at $16.70 and has been a dream stock for shareholders. It’s returned 283% since July 2021, blowing past the S&P 500’s 72.3% gain. The... 
Via StockStory
Topics Stocks
News headline image
Generic Pharmaceuticals Stocks Q4 In Review: Amneal (NASDAQ:AMRX) Vs Peers
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the generic pharmaceuticals industry, including Amneal (NASDAQ:AM... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
1 Mooning Stock Worth Your Attention and 2 We Question
Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such a... 
Via StockStory
News headline image
1 Small-Cap Stock for Long-Term Investors and 2 We Find Risky
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that ... 
Via StockStory
News headline image
3 Russell 2000 Stocks with Open Questions
The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size ... 
Via StockStory
News headline image
Amneal Pharmaceuticals Bets on Biosimilars, Patches to Power Next Growth Phase ↗
Amneal Pharmaceuticals (NASDAQ:AMRX) Co-Founder, President and Co-Chief Executive Officer Chirag Patel said the company is entering a stronger growth phase, driven by momentum in its existing generics... 
Via MarketBeat
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.